3 Beaten-Up Biotech Stocks: Are They Bargains?
The iShares Nasdaq Biotechnology Index has tacked on a healthy gain of around 15% so far this year, without any help from Celldex Therapeutics, Inc. (NASDAQ: CLDX), Agenus Inc. (NASDAQ: AGEN), or Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX). All three of these relatively small biotechs have slipped by double-digit percentages in 2017.
Is the pessimism justified, or has the market underestimated the potential value drivers within these companies' drug development pipelines? Let's take a cool-headed look at each to see if there's something for long-term value investors to get excited about.
Beaten-down prices for these biotech stocks suggest value opportunities ahead. Image source: Getty Images.
Source: Fool.com
Celldex Therapeutics Aktie
37,80 €
-
Positive Community-Reaktionen für Celldex Therapeutics mit mehreren Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Community-Kursziel von 62 € für Celldex Therapeutics deutet auf eine deutliche Steigerung um mehr als 50% gegenüber dem aktuellen Kurs von 37.8 € hin.
